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Bach2 is a transcriptional repressor that is expressed during
speciﬁc stages of B-cell development and in neuronal cells. It
plays a critical role in modulating class-switch recombination
during the differentiation of mature B cells to antibody-
secreting plasma cells and it is also an important regulator
of apoptotic responses to oxidative stress. Bach2 has been
implicated both as an oncogene and as a tumour suppressor
in human malignancy. The interaction of Bach2 with its target
genes is mediated via its basic leucine-zipper region, whereas
the N-terminal POZ domain recruits transcriptional co-
repressors and class II histone deacetylases. Here, the crystal
structure of the human Bach2 POZ domain is reported at
2.1 A˚ resolution. The Bach2 POZ-domain dimer resembles
the POZ-domain dimers of the POZ zinc ﬁnger transcription
factors and dimerization is independent of an N-terminal
region that has previously been implicated in the dimerization
of the POZ basic leucine-zipper protein Bach1. The Bach2
POZ domain crystallized in two forms which differed by the
presence of an intersubunit disulﬁde bond. The intersubunit
disulﬁde bond is present both in bacterially expressed Bach2
POZ domain in solution and in protein expressed in trans-
fected eukaryotic cells. These crystal structures will be relevant
for understanding the regulation of Bach2 in response to
oxidative stress and for the design of therapeutics that target
the Bach2 POZ domain in human malignancy.
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Accepted 14 November 2011
PDB References: human
Bach2 POZ domain, Cys20
reduced, 3ohu; Cys20
oxidized, 3ohv.
1. Introduction
The Bach (bric-a`-brac, tramtrack and broad complex and
cap’n’collar homology) family transcription factors Bach1 and
Bach2 are CNC (cap’n’collar) type bZip (basic leucine zipper)
proteins that contain an N-terminal BTB [bric-a`-brac, tram-
track and broad complex; also known as POZ (poxvirus and
zinc ﬁnger)] domain (Oyake et al., 1996) that mediates tran-
scriptional repression. Bach1 is ubiquitously expressed,
whereas Bach2 is found mainly in neuronal cells and during
speciﬁc stages of B-cell differentiation. Bach1 and Bach2
interact with the small Maf (musculoaponeurotic fibro-
sarcoma) proteins via their leucine-zipper regions to form
heterodimers that bind MARE (Maf recognition element)
sequences within target genes (Oyake et al., 1996; Muto et al.,
1998).
Bach2 plays a role in the late stages of B-cell development
and is also a critical component of the transcription-factor
network that regulates the terminal differentiation of mature
B cells to antibody-secreting plasma cells (reviewed in Igar-
ashi et al., 2007). Bach2 is highly expressed throughout the
pro-B to mature B-cell stages (Muto et al., 1998), during which
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it represses transcription of the Blimp-1 (B lymphocyte-
induced maturation protein-1) gene; Blimp-1 is required for
terminal differentiation to plasma cells. Bach2 levels decrease
upon B-cell activation following antigen exposure, leading to
Blimp-1 induction and the concomitant differentiation of B
cells into IgM antibody-producing plasma cells. During anti-
body responses, class-switch recombination (CSR) of the
immunoglobulin genes leads to the production of additional
antibody classes, such as IgG, which have different effector
functions. CSR is mediated by the transient induction of
activation-induced cytidine deaminase (AID) following B-cell
activation; importantly, AID is no longer expressed in term-
inally differentiated plasma cells. The reduction in Bach2
levels is heterogenous between individual activated B cells
and leads to a variation in the timing of Blimp1 induction and
in the rate of differentiation to plasma cells; this allows a time
window that delays differentiation in those cells with higher
Bach2, thereby enabling AID-mediated class-switch recom-
bination to occur (Muto et al., 2010). Mice that are deﬁcient
in Bach2 have reduced numbers of mature B cells, enhanced
rates of differentiation to plasma cells and decreased CSR
(Muto et al., 2004). Bach2 thus plays a crucial role in repres-
sing Blimp1 expression in activated B cells long enough to
delay differentiation and thereby allowing CSR to occur, and
the heterogenous decline in Bach2 explains the stochastic
nature of plasma-cell differentiation and of CSR.
The activity of Bach2 is modulated by its nucleocytoplasmic
shuttling, which is regulated by the PI3 (phosphoinositide 3)
kinase pathway and by oxidative stress. Following B-cell
activation, the phosphorylation of Ser521 by PI3 kinase leads
to the movement of Bach2 from the nucleus to the cytoplasm,
thereby promoting plasma-cell differentiation and inhibiting
CSR (Yoshida et al., 2007). Bach2 also plays an important role
in modulating the cellular responses to oxidative stress, in part
by repressing transcription of the haem oxygenase-1 (HO-1)
gene (Yoshida et al., 2007), which has anti-apoptotic functions
and cytoprotective effects against oxidative injury. Low levels
of oxidative stress lead to the phosphorylation of Bach2 and
retention in the cytoplasm, resulting in derepression of the
anti-apoptotic HO-1 gene and allowing cells to repair and
survive. In contrast, high levels of oxidative stress lead to
the dephosphorylation and nuclear import of Bach2, resulting
in repression of HO-1 and concomitant apoptosis. Bach2 is
thought to regulate apoptotic responses to the oxidative stress
that is associated with B-cell development and also to
modulate responses to chemotherapeutic agents that induce
oxidative stress (Kamio et al., 2003). The cytoplasmic retention
of Bach2 is directed by its C-terminal cytoplasmic localization
signal (Hoshino et al., 2000), whereas the N-terminal POZ
domain is required for the association of Bach2 with PML
(promyelocytic leukaemia protein) bodies in the nucleus
(Tashiro et al., 2004).
Bach2 has been implicated both as an oncogene and as a
tumour suppressor in human malignancies. The BCR-ABL
(breakpoint cluster region-Abelson) fusion protein that is
expressed in chronic myelogenous leukaemia activates signal-
ling pathways that lead to the increased phosphorylation and
nuclear export of Bach2, resulting in enhanced cell survival
owing to resistance to oxidative stress (Yoshida et al., 2007).
Treatment of leukaemic cells with the BCR-ABL inhibitor
ST1571 leads to elevated nuclear Bach2 and increased apop-
tosis; apoptosis is further enhanced by simultaneous treatment
with oxidative stressors. Expression of the anti-apoptoticHO-1
gene is high in some malignancies (Hara et al., 1996) and the
resistance of myeloma cells to ROS-induced (reactive oxidant
species) apoptosis is associated with increased HO-1 levels
and reduced Bach2 levels (Zhou et al., 2005). In contrast to its
role as a tumour suppressor, Bach2 has been implicated as an
oncogene in leukaemic cells that have chromosome translo-
cations that juxtapose the Bach2 gene to the IgH locus
(Kobayashi et al., 2011). Additionally, Bach2 overexpression
has been reported in some non-Hodgkin’s lymphoma cell lines
that carry an Ig-Myc (myelocytoma) translocation (Kobayashi
et al., 2011) and overexpression of Bach2 has been correlated
with a poor prognosis in epithelial ovarian cancer (Motamed-
Khorasani et al., 2007). The contrasting roles of Bach2 in
different human malignancies is most likely to reﬂect its
opposing functions in preventing differentiation and pro-
moting apoptosis.
The POZ domain is a protein–protein interaction domain
that is found in approximately 40 mammalian transcription
factors (POZ-TFs); POZ domains mediate interactions with
transcriptional co-regulators and also direct speciﬁc inter-
actions of the POZ-TFs with each other (reviewed in Stogios
et al., 2005). Most POZ-TFs contain a zinc-ﬁnger DNA-
binding domain and several members of this family have been
extensively studied owing to their role in human malignancy.
For example, the BCL6 (B-cell lymphoma 6) oncogene is
overexpressed in follicular lymphoma and in diffuse large-cell
B-cell lymphoma and structural studies of the interactions of
the BCL6 POZ domain with its transcriptional co-repressors
B-CoR (BCL6-interacting co-repressor; Ghetu et al., 2008)
and SMRT (silencing mediator for retinoid and thyroid
hormone receptors; Ahmad et al., 2003) led to the design of
inhibitors that may be developed into therapeutics (Cerchietti
et al., 2010, 2009). The target gene repertoire of the POZ-TFs
is increased via their heteromeric interactions with each other;
for example, the interaction between BCL6 and the POZ-TF
Miz1 (Myc-interacting zinc ﬁnger 1) leads to the recruitment
of BCL6 to Miz1 target genes (Phan et al., 2005) and is
important in suppressing Miz1 targets during the germinal
centre reaction in B cells. The Bach2 POZ domain interacts
with the POZ zinc-ﬁnger protein MAZR (Myc-associated
zinc-ﬁnger protein related factor; Kobayashi et al., 2000) and
Bach2 also interacts with BCL6 in a POZ-independent manner
(Ochiai et al., 2008). The Bach2 POZ domain represses tran-
scription via the recruitment of class II histone deacetylases
and SMRT (Hoshino et al., 2007), although the POZ domains
of the POZ bZip proteins are not well characterized and
detailed structures of their interactions are not available.
We report the crystal structure of the human Bach2 POZ
domain to 2.1 A˚ resolution. The overall structure resembles
the POZ domains of the POZ zinc-ﬁnger factors and, in
contrast to a previous report (Ito et al., 2009), suggests that
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dimerization of the POZ bZip POZ domains does not require
an N-terminal hook. The structure of the Bach2 POZ domain
reveals an intersubunit disulﬁde bond that is also observed in
puriﬁed protein in solution and in vivo.
2. Materials and methods
2.1. Cloning
DNA fragments encoding the human Bach2 POZ domain
(Bach2 residues 9–129 and residues 2–132) were ampliﬁed by
PCR from a human placental cDNA library and inserted into
the bacterial expression vector pGEX-6P-1 (GE Healthcare)
as BamHI–XhoI restriction-enzyme fragments. The resulting
plasmids encoded fusion proteins containing an N-terminal
GST tag and a PreScission protease cleavage site. The human
Bach2 POZ domain C20S mutation was generated by PCR
with Phusion High-Fidelity DNA polymerase (Finnzymes)
using the oligonucleotides GAGTCCACAGTCCACTCCA-
CCAACATCCTCCTGGGC and ATACACATACATGGG-
GGAGTCAGGCTTCTCATCCAC. The C125S mutation was
generated using the oligonucleotides CTGGAGGACTCCT-
CCTTCAGCTTCCTGCAGACC and GTTGTGCATGCGC-
AGGAACTCAGCACAGCG.
The mouse Bach2 POZ domain (residues 2–132) was
ampliﬁed by PCR from a mouse ES cell cDNA library and
was cloned into the mammalian expression vector pcDNA3
(Invitrogen); an oligonucleotide encoding a FLAG-tag was
inserted at the N-terminus of the POZ domain and an oligo-
nucleotide encoding the c-Myc nuclear localization signal was
inserted at the C-terminus. The mouse Bach2 POZ domain
C20S mutation was generated as above using the oligo-
nucleotides GAGTCCACAGTCCACTCTGCCAACATCCT-
CCTG andATATACATACATGGGGGAGCCAGGCTTCTC.
2.2. Protein expression and purification
The plasmids were transformed into Escherichia coli BL21
(DE3) pLysS cells using the heat-shock method and plated
on Luria–Bertani agar plates containing 34 mg l1 chloram-
phenicol and 100 mg l1 ampicillin. Cells were cultured over-
night with shaking at 310 K in 2TY medium containing the
same antibiotics. 100 ml of the overnight culture was subse-
quently inoculated into 10 l 2TY medium supplemented with
100 mg l1 ampicillin and the cells were grown at 310 K with
shaking to an optical density at 600 nm of 0.6–0.8. Expression
of recombinant protein was induced with isopropyl -d-1-
thiogalactopyranoside at a ﬁnal concentration of 0.1 mM and
the cells were incubated at 289 K for 16 h. The cells were
harvested by centrifugation and the cell pellets were stored at
193 K until required.
A bacterial pellet from a 10 l culture was resuspended in
lysis buffer [PBS containing 0.1% Triton X-100 and 5 mM
dithiothreitol (DTT) pH 7.5] and the cells were lysed using
a French press. The lysate was clariﬁed by centrifugation at
39 000g for 20 min and the supernatant was passed through
a 0.45 mm ﬁlter. Fusion proteins were bound to glutathione-
Sepharose 4B that had been pre-equilibrated with lysis buffer.
Nonspeciﬁcally bound proteins were removed from the
glutathione-Sepharose 4B by alternating washes in lysis buffer
and in lysis buffer supplemented with 1M NaCl. The gluta-
thione-Sepharose 4B was further rinsed with 20 mM Tris–HCl,
75 mMNaCl, 5 mMDTT pH 7.5 and the GST tag was removed
by cleavage with PreScission protease. Bach2 POZ domains
were further puriﬁed by size-exclusion chromatography on
a pre-equilibrated HiLoad Superdex 75 26/60 column (GE
Healthcare) in 20 mM Tris–HCl, 150 mM NaCl, 5 mM DTT,
5% glycerol pH 7.9. Puriﬁed Bach2 POZ domains eluted at
a concentration of 0.2 mg ml1 and were concentrated to
12 mg ml1 using Amicon Ultra centrifugal concentrators
(Millipore).
2.3. Protein crystallization
Crystallization trials were set up in 96-well Corning 3552
crystallization trays using an Oryx 6 robot (Douglas Instru-
ments Ltd). A variety of commercially available sparse-matrix
crystallization screens were used and crystals of the human
Bach2 POZ domain (residues 9–129) were obtained in 0.2M
ammonium sulfate, 0.1M bis(2-hydroxyethyl)amino-tris(hy-
droxymethyl)methane pH 5.5, 25%(w/v) PEG 3350 at 291 K
using a protein concentration of 6.5 mg ml1. Optimization of
the crystallization conditions was carried out by sitting-drop
vapour diffusion in MVD-24 plates (NBS Biologicals). Crys-
tals with average dimensions of 100  30 30 mm were grown
by mixing 2 ml protein solution (9 mg ml1) with 2 ml reservoir
solution [0.2M ammonium sulfate, 0.1M 2-(N-morpholino)-
ethanesulfonic acid pH 5.5, 4%(w/v) PEG 3350] and incu-
bating at 291 K for 4–5 d. Crystals were harvested with a nylon
cryoloop and transferred into a 5 ml drop of 0.2M ammonium
sulfate, 0.1M 2-(N-morpholino)ethanesulfonic acid pH 5.5,
4%(w/v) PEG 3350, 17.5% glycerol. They were soaked for 30 s
in this solution before being cooled to 100 K.
2.4. Data collection, structure determination and refinement
X-ray diffraction data were collected on beamline I02 at
Diamond Light Source, processed using MOSFLM (Leslie,
1992) and scaled using SCALA (Evans, 2006). The human
Bach2 POZ domain (residues 9–129) crystallized in space
group P21. A Matthews coefﬁcient corresponding to a bulk-
solvent content of 52% suggested the presence of six mole-
cules in the asymmetric unit. The structure was solved by
molecular replacement using Phaser (McCoy et al., 2007) with
the human Bach1 POZ domain (PDB entry 2ihc; Structural
Genomics Consortium, unpublished work) as the search
model.
Initial models were built using ARP/wARP (Cohen et al.,
2008) and underwent density modiﬁcation using Parrot
(Zhang et al., 1997). Several rounds of iterative model building
and reﬁnement were performed using Coot (Emsley et al.,
2010) and REFMAC5 (Murshudov et al., 2011); 5% of the data
were excluded from reﬁnement and used for cross-validation.
Later rounds of reﬁnement included TLS reﬁnement with two
groups per POZ-domain monomer (Painter & Merritt, 2006);
TLS parameters were calculated using the TLSMD web server
research papers
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(http://skuld.bmsc.washington.edu/~tlsmd). Geometry was
analysed using PROCHECK (Laskowski et al., 1993) and
MolProbity (Chen et al., 2010). R.m.s.d values for the POZ
domains were calculated using the SuperPose (Maiti et al.,
2004) server (http://wishart.biology.ualberta.ca/SuperPose).
OMIT maps were generated using SFCHECK (Vaguine et
al., 1999) and images of the protein structures were prepared
using CCP4MG (Potterton et al., 2004).
2.5. SDS–PAGE under reducing and nonreducing conditions
Wild-type, C20S, C125S and C20S/C125S mutant human
Bach2 POZ domains were expressed in E. coli and puriﬁed
as described above. Samples for reduction were treated with
-mercaptoethanol to a ﬁnal concentration of 5% and samples
for oxidation were treated with hydrogen peroxide to a ﬁnal
concentration of 0.05–5 mM for 1 h at room temperature.
All samples were heated for 5 min at 368 K in 62.5 mM Tris–
HCl, 2% SDS, 10% glycerol, 0.05% Bromophenol Blue and
analysed by SDS–PAGE (Laemmli, 1970) using 15% gels.
Proteins were visualized by staining with Coomassie R-250.
2.6. Transfection of eukaryotic cells
COS-7 cells were transfected with expression vectors
encoding FLAG-tagged mouse Bach2 POZ domains (wild
type and C20S mutant) using the calcium phosphate precipi-
tation method (Wigler et al., 1979). Cells were harvested 48 h
after transfection and lysed in 50 mM Tris–HCl, 150 mMNaCl,
1 mM EDTA, 1% Triton X-100 pH 7.4. Samples were
electrophoresed on SDS–polyacrylamide gels and transferred
to a nitrocellulose membrane. The membrane was probed with
1:2000 rabbit polyclonal anti-FLAG antibody (Sigma–
Aldrich) followed by 1:10 000 HRP-conjugated anti-rabbit
IgG (Pierce) before being exposed to X-ray ﬁlm.
3. Results
3.1. Structural features of the human Bach2 POZ domain
The Bach2 POZ domain (residues 9–129) crystallized in
space group P21 with three POZ-domain dimers in the
asymmetric unit. The overall structure of the Bach2 POZ
dimer resembles the reported POZ dimers of the POZ zinc-
ﬁnger transcription factors.
It was apparent upon solving the structure that the Bach2
POZ domain crystallized in two forms, form I and form II,
which differ in the oxidation state of the Cys20 residue located
at the N-terminus of the 1 helix in the dimerization interface
(Table 1 and Fig. 1a). Both crystal forms grew under identical
conditions. Cys20 is in a reduced state in all six Bach2 chains
in the asymmetric unit of the form I crystals, whereas all Bach2
dimers in the form II crystals contain a Cys20 intersubunit
disulﬁde bond. OMIT maps were calculated and conﬁrmed
the electron density in the vicinity of Cys20 (Supplementary
Fig. S11). A disulﬁde bond is also present between the Cys125
residues of two neighbouring POZ dimers in the form II
crystal structure; the orientation of the other molecules in the
asymmetric unit of this crystal is not compatible with the
formation of Cys125 disulﬁde bonds. Cys125 is reduced in all
chains of the form I crystals and all other cysteine residues are
reduced in both forms I and II. The overall structures of the
POZ-domain dimers in the form I and II crystals are otherwise
identical, with an r.m.s.d. value of C-atom positions of 0.2 A˚,
and there are no differences in the positions of the side chains
in the vicinity of Cys20. We also crystallized a slightly longer
version of the human Bach2 POZ domain (residues 2–132)
using different crystallization conditions; although these
crystals diffracted to only 3 A˚ resolution it was clear that this
longer protein also crystallized in two forms that differed in
the oxidation state of Cys20 (data not shown).
The overall organization of the Bach2 POZ domain is
similar to the previously reported POZ-domain dimers of
PLZF (promyelocytic leukaemia zinc finger; Ahmad et al.,
1998), BCL6 (Ahmad et al., 2003; Stead et al., 2008), LRF
(leukaemia/lymphoma related factor; Schubot et al., 2006),
Miz1 (Stead et al., 2007; Stogios et al., 2010) and Nac1 (nuclear
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Table 1
Data-collection and processing statistics.
Values in parentheses are for the highest resolution shell.
Bach2 form I
(Cys20 reduced)
Bach2 form II
(Cys20 oxidized)
Crystal parameters
Space group P21 P21
Unit-cell parameters
(A˚, )
a = 55.60, b = 96.97,
c = 82.63,  = 90.00,
 = 101.06,  = 90.00
a = 55.68, b = 96.95,
c = 82.48,  = 90.00,
 = 101.06,  = 90.00
Data collection
Resolution (A˚) 54.57–2.10 (2.21–2.10) 48.48–2.20 (2.32–2.20)
Wavelength (A˚) 0.9795 0.9795
Rmerge† (%) 9.3 (72.6) 10.5 (71.8)
Rp.i.m.‡ (%) 6.1 (47.7) 6.9 (47.7)
hI/(I)i 9.2 (2.9) 8.9 (1.7)
No. of unique reﬂections 49842 (7295) 43314 (6332)
Multiplicity 3.1 (3.1) 3.1 (3.1)
Completeness (%) 99.2 (99.7) 99.2 (99.7)
Reﬁnement
Resolution (A˚) 40.55–2.10 48.48–2.20
R§ (%) 21.0 22.3
Rfree} (%) 25.7 27.3
R.m.s.d. stereochemistry††
Bond lengths (A˚) 0.011 0.011
Bond angles () 1.3 1.3
No. of protein atoms 5710 5731
No. of water molecules 276 216
Average B factor (A˚2) 38.6 31.7
Ramachandran analysis‡‡ (%)
Favoured 97.6 96.1
Allowed 2.4 3.9
Disallowed 0.0 0.0
PDB code 3ohu 3ohv
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the integrated
intensity of a given reﬂection and hI(hkl)i is the mean intensity of multiple corresponding
symmetry-related reﬂections. ‡ Rp.i.m. =
P
hkl ½1=ðN  1Þ1=2
P
i jIiðhklÞ  hIðhklÞij=P
hkl
P
i IiðhklÞ, where Ii(hkl) is the integrated intensity of a given reﬂection, hI(hkl)i
is the mean intensity of multiple corresponding symmetry-related reﬂections and N is the
multiplicity of a given reﬂection. § R =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where Fobs
and Fcalc are the observed and calculated structure factors, respectively. } Rfree is R
calculated using a random 5% of data excluded from the reﬁnement. †† R.m.s.d
stereochemistry is the deviation from ideal values. ‡‡ Ramachandran analysis was
carried out using MolProbity (Chen et al., 2010).
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: GM5019). Services for accessing this material are described at the
back of the journal.
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Figure 1
Structure of the human Bach2 POZ domain. (a) Ribbon representation of the form I (Cys20 reduced) and form II (Cys20 oxidized) structures of the
human Bach2 POZ domain. Secondary-structure elements of the A subunit are labelled; a prime (0) indicates a secondary-structure element of the B
chain. The lower images depict an enlargement of the region surrounding the Cys20 residue; S atoms are coloured orange. A 2Fo  Fc electron-density
map is shown contoured at 1.5. The charged pocket and lateral grooves are indicated; these regions have previously been described in other POZ-
domain proteins (Ahmad et al., 1998, 2003). (b) Size-exclusion chromatograpy of wild-type and mutant Bach2 POZ domains using Superdex 75. The top
left trace represents the elution proﬁle of marker proteins (low-molecular-weight gel-ﬁltration calibration kit; GE Healthcare). Sizes are indicated in
kDa. The wild-type and mutant Bach2 POZ domains eluted at volumes corresponding to dimeric species.
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accumbens associated 1; Stead et al., 2009), in which a central
core of -helices is ﬂanked by short -sheets. Compared with
the Bach2 POZ domain (form I), the r.m.s.d. values for
C-atom positions are 2.6 A˚ for PLZF (PDB entry 1buo),
1.8 A˚ for BCL6 (PDB entry 1r28), 2.9 A˚ for LRF (PDB entry
2nn2) and 1.1 A˚ for Bach1 (PDB entry 2ihc). In agreement
with reported POZ-domain structures, the Bach2 POZ
domain is a domain-swapped dimer with two types of inter-
action interface: a central hydrophobic core that involves
interactions from 1, 2 and 3 and that buries approximately
1200 A˚2 of surface area per monomer, together with two
-strand interfaces that comprise interactions between the 1
strand of one chain and 5 of the other and which bury an
additional 1000 A˚2 of surface area per monomer (Fig. 1a).
The C-termini of the BCL6, LRF, PLZF and Miz1 POZ
domains form an -helix (6) that lies adjacent to 5; how-
ever, as observed in Nac1 (Stead et al., 2009) this region is
unstructured in the Bach2 POZ domain. 6 is not part of the
POZ-domain core fold and the residues within this region are
the least conserved in both sequence and structure among the
various POZ domains.
3.2. Dimerization of the Bach2 POZ domain does not require
an N-hook
The POZ-domain sequences of the bZip transcription
factors Bach1 and Bach2 are more closely related to each
other than they are to those of POZ zinc-ﬁnger transcription
factors (Fig. 2). The crystal structures of the human and mouse
(Ito et al., 2009) dimeric Bach1 POZ domains have recently
been reported (PDB entries 2ihc and 2z8h, respectively;
Structural Genomics Consortium, unpublished work; Ito et al.,
2009). In addition to the classic POZ-domain dimerization
interfaces, the mouse Bach1 POZ-domain structure revealed
an interaction between the N-terminal six residues of one
chain and the very C-terminal residues of the opposite strand;
these N-terminal residues that precede 1 have been dubbed
the ‘N-hook’. Analytical ultracentrifugation experiments
showed that the wild-type Bach1 POZ domain is dimeric,
whereas the sedimentation proﬁle of a truncated protein that
lacked the N-hook was interpreted as representing a mono-
meric species (Ito et al., 2009). The N-terminal region of Bach2
(residues 1–9) contains an insertion of three residues
compared with Bach1 (Fig. 2) and in the same analytical
ultracentrifugation studies it was suggested that the sedi-
mentation proﬁle of puriﬁed Bach2 POZ domain represents
that of a monomeric species. It was hypothesized that the
N-hook is essential for dimerization of the Bach1 POZ domain
and that Bach2 fails to dimerize because its N-terminus is
unable to form this structure. It was therefore proposed that
the mechanism of POZ-domain dimerization in the bZip
factors differs from that observed in the POZ zinc-ﬁnger
proteins.
In contrast to the reported study (Ito et al., 2009), the
human Bach2 POZ proteins (residues 2–132 and 9–129) that
we expressed and puriﬁed both eluted as dimers during size-
exclusion chromatography (Fig. 1b) and both crystallized as
dimers using a variety of crystallization conditions (Fig. 1a and
data not shown). This suggests that the N-terminal residues of
Bach2 (residues 1–8) do not inﬂuence its dimerization, which
is mediated solely by the classic POZ-domain interaction
interfaces as observed in the POZ zinc-ﬁnger transcription
factors. Of note, the crystal structure of the human Bach1 POZ
domain (PDB entry 2ihc, residues 7–128) lacks the putative
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Figure 2
POZ-domain sequence alignment. Sequence alignment of a selection of human POZ-TF POZ domains; sequences were aligned using ClustalW
(Thompson et al., 1994). The observed secondary-structure elements of the Bach2 POZ-domain chains are indicated; -helices are depicted as red
cylinders and -strands as blue arrows. The pink cylinder represents the sequence that corresponds to 6 in many POZ-TFs. All cysteine residues of the
Bach2 POZ domain are highlighted in green and conserved cysteines of other POZ proteins are also indicated.
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N-hook, thereby questioning the role of this region in regu-
lating POZ-domain dimerization in the POZ bZip factors.
3.3. Formation of an intersubunit disulfide bond in the Bach2
POZ-domain dimer in vitro and in vivo
We determined whether the intersubunit disulﬁde bond
observed in the human Bach2 POZ-domain crystals is also
present in puriﬁed protein in solution and in protein expressed
in eukaryotic cells in vivo. In order to abolish Cys20 disulﬁde
bonds, we generated a human Bach2 POZ C20S mutant and
puriﬁed recombinant protein that had been expressed in
E. coli; the Bach2 POZ C20S mutant eluted solely as a dimer
during size-exclusion chromatography (Fig. 1b). Puriﬁed wild-
type and C20S Bach2 POZ domains were analysed by SDS–
PAGE under both reducing and nonreducing conditions.
Samples were either reduced by treatment with 20 mM DTT
or oxidized by treatment with hydrogen peroxide. The wild-
type POZ domain formed both dimers and higher-order
oligomers under nonreducing conditions, with higher-order
oligomerization being increased at higher concentrations of
hydrogen peroxide (Fig. 3a). Dimerization under nonreducing
conditions was signiﬁcantly decreased in the C20S mutant
and higher-order oligomers were virtually absent (Fig. 3b).
This suggested that Cys20 residues form intersubunit disulﬁde
bonds within the POZ-domain dimer in solution and that an
additional cysteine residue is most likely to be involved in the
formation of disulﬁde bonds that link POZ-domain dimers
into higher-order oligomers. Analysis of the crystal structure
revealed that Cys125 is the only surface-exposed cysteine
residue; we therefore made a C125S mutant and a C20S/C125S
double mutant of the human Bach2 POZ domain. The C125S
Bach2 POZ domain migrated as a dimer under oxidizing
conditions, whereas all oligomerization was abolished in
experiments with the C20S/C125S double mutant (Fig. 3c).
The higher-order oligomerization of the wild-type human
Bach2 POZ domain observed under nonreducing conditions
in solution is therefore consistent with the formation of Cys20
disulﬁde bonds between the subunits of the POZ-domain
dimer, together with Cys125 disulﬁde bonds that link the
POZ-domain dimers into oligomers.
To determine whether the Bach2 POZ domain contains
an intersubunit disulﬁde bond in vivo, we expressed FLAG-
tagged wild-type and C20S mutant mouse Bach2 POZ
domains in COS-7 cells and analysed cell lysates by Western
blotting following SDS–PAGE under nonreducing and
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Figure 3
Disulﬁde-bond formation in the puriﬁed human Bach2 POZ domain in solution. (a) Analysis of puriﬁed wild-type Bach2 POZ-domain protein by SDS–
PAGE. The sample in lane 1 contained 20 mM DTTand the samples in lanes 2–8 were treated with various concentrations of hydrogen peroxide for 1 h
at room temperature and electrophoresed under nonreducing conditions. (b) Analysis of puriﬁed C20S Bach2 POZ-domain protein by SDS–PAGE.
Samples were treated as described in (a). (c) Puriﬁed wild-type Bach2 POZ-domain protein, together with the C20S, C125S and C20S/C125S mutants,
was analysed by SDS–PAGE. Reduced samples were treated with 5% -mercaptoethanol (Me). Oxidized samples were incubated with 1 mM hydrogen
peroxide for 1 h at room temperature.
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reducing conditions. Under nonreducing conditions the wild-
type mouse Bach2 POZ domain migrated as both a monomer
and a dimer, whereas the C20S mutant was monomeric (Fig.
4). This suggests that Cys20 mediates the formation of inter-
subunit disulﬁde bonds in the Bach2 POZ domain in vivo and
that the Cys125 disulﬁde bonds that we observed in bacterially
expressed protein in solution were most likely to be a reﬂec-
tion of the high protein concentration in vitro.
4. Discussion
Reversible disulﬁde-bond formation is often used as a
mechanism to regulate the activity of proteins involved in
oxidative stress responses. Regulatory disulﬁde bonds are
sometimes formed between distantly related cysteine residues,
resulting in large conformation changes that modulate speciﬁc
properties of the protein. For example, oxidation of the
prokaryotic transcriptional regulator OhrR (organic hydro-
peroxide resistance R) by organic hydroperoxides leads to the
formation of an intersubunit disulﬁde bond that results in a
large conformation change; this weakens the interaction of
OhrR with the DNA backbone and allows the derepression of
genes that reduce the hydroperoxides to less toxic alcohols
(Newberry et al., 2007). Disulﬁde-bond formation may also
directly stabilize subunit interactions within a protein or may
inﬂuence protein–protein interactions. A disulﬁde bond is the
main feature that stabilizes the dimerization interface of the
activation domain of the bovine papilloma virus E2 protein
(Sanders et al., 2007); tight dimerization of this region abro-
gates its interaction with the viral E1 protein, thereby regu-
lating E2 function in response to oxidative stress. Oxidative
stress also leads to the inhibition of speciﬁc protein–protein
interactions in the yeast transcriptional activator Yap1
(Yamaguchi sarcoma viral oncogene-associated protein 1;
Wood et al., 2004); disulﬁde-bond formation masks the nuclear
export signal and prevents interaction with the CRM1
exporter, resulting in nuclear retention of Yap1 and the
transcriptional activation of oxidative-stress response genes.
Disulﬁde bonds may also be involved in directly mediating
speciﬁc protein–protein interactions in response to oxidative
stress: oxidation of the yeast tyrosine phosphatase Sdp1
(stress-inducible dual-speciﬁcity MAP kinase phosphatase 1)
leads to the formation of a disulﬁde bond that forms part of
a deep cleft involved in the speciﬁc recognition of substrate
phosphotyrosine residues (Fox et al., 2007). The intersubunit
disulﬁde bond of the Bach2 POZ domain is not required for
stabilization of the dimerization interface and does not lead
to conformation changes within the POZ-domain dimer. The
disulﬁde bond formed readily in crystals and in solution, even
though the protein was puriﬁed in the presence of 5 mM DTT,
and was observed in crystals under conditions in which other
cysteines were reduced. Myoneurin, a protein expressed in
muscle, is the only other POZ-TF with a cysteine residue
located at the start of the 1 helix at a position corresponding
to Cys20 in Bach2; the crystal structure of the myoneurin
POZ-domain dimer (PDB entry 2vpk; C. D. O. Cooper, J. W.
Murray, A. Bullock, A. C. W. Pike, F. Vondelft, P. Filippako-
poulos, E. Salah, A. Edwards, C. H. Arrowsmith, C. Bountra,
J. Weigelt & S. Knapp, unpublished work) revealed an inter-
subunit disulﬁde bond at this position. Other cysteine residues
of the Bach2 POZ domain are conserved among most POZ-
TF POZ domains, with the exception of Cys112, which is only
found in the POZ bZip protein Bach1, a protein that is also
regulated by oxidative stress.
The dimeric organization of the Bach2 POZ domain implies
that this interaction will direct the higher-order association of
Bach2–Maf heterodimers, analogous to the reported oligo-
merization of Bach1–Maf complexes (Igarashi et al., 1998).
Such interactions are predicted to facilitate the cooperative
binding to multiple MARE sequences within target genes.
The physiological role of the intersubunit disulﬁde bond in
the Bach2 POZ-domain dimer is presently unknown and it is
not known whether it is part of the mechanism for sensing
oxidative stress during B-cell development. It will be relevant
to determine whether this disulﬁde bond affects the inter-
actions of Bach2 with other POZ partners or with transcrip-
tional co-repressors and whether it is involved in the
mechanism that determines the subnuclear localization of
Bach2 in response to oxidative stress.
The structure of the Bach2 POZ domain will aid in the
development of therapeutics for those human malignancies in
which Bach2 is overexpressed. In a manner analogous to the
targeting of BCL6 in diffuse large B-cell lymphoma (Cerch-
ietti et al., 2009, 2010), peptides or small molecules could
potentially be used to inhibit the interactions of the Bach2
POZ domain with histone deacetylases and the transcriptional
co-repressor SMRT. Such approaches would require the
characterization of the interfaces that mediate the interactions
between Bach2 and its co-repressors; it is not yet known
whether the lateral groove of the Bach2 POZ domain is a
critical site of such interactions and whether its co-repressor
binding region thus resembles that of BCL6. X-ray crystal
structures of the Bach2 POZ domain could then be used to
develop inhibitors of co-repressor interactions using both
virtual screening and rational design.
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Figure 4
Oligomeric state of FLAG-tagged mouse Bach2 POZ domains expressed
in COS-7 cells. Wild-type and C20S mutant FLAG-tagged Bach2 POZ
domains were expressed in COS-7 cells and the proteins were analysed by
SDS–PAGE under nonreducing (lanes 1 and 2) and reducing (lanes 3 and
4) conditions.
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